Gossamer Announces Up to $250M Financing with Conditional Tranches
Gossamer Bio (NASDAQ: GOSS) announced an up-to-$250 million private placement, structured in three tranches. The first tranche is expected to raise approximately $25 million upfront through pre-funded warrants priced at $0.1399 per share. Additional funding of $125 million and $100 million will be contingent on the FDA accepting or approving seralutinib for pulmonary arterial hypertension, respectively. The company currently holds about $57 million in cash and had previously expected this to fund operations through early 2027. The initial tranche is intended to extend that runway but not fully secure it until a potential approval decision. Gossamer plans to submit the application for seralutinib by September 2026, with management indicating FDA concerns are review-related rather than disqualifying. However, risks remain: the second and third tranches depend on regulatory outcomes that are not guaranteed. The financing also involves significant dilution, potentially increasing outstanding shares substantially.
Tickers: $GOSS
Topics: biotech cash_runway funding_rounds private_placement